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Background: Point-of-care (POC) tests for COVID-19 could relieve pressure on isolation resource, 
support infection prevention and control, and help commence more timely and appropriate 
treatment.  We aimed to undertake a systematic review and pooled diagnostic test accuracy study of 
available individual patient data (IPD) to evaluate the diagnostic accuracy of a commercial POC test 
(FebriDx) in patients with suspected COVID-19. 
 
Methods: A literature search was performed on the 1st of October 2020 to identify studies reporting 
diagnostic accuracy statistics of the FebriDx POC test versus real time reverse transcriptase 
polymerase chain reaction (RT-PCR) testing for SARS-CoV-2. Studies were screened for risk of bias. 
IPD were sought from studies meeting the inclusion and exclusion criteria. Logistic regression was 
performed to investigate the study effect on the outcome of the RT-PCR test result in order to 
determine whether it was appropriate to pool results. Diagnostic accuracy statistics were calculated 
with 95% confidence intervals (CIs).  
 
Results: 15 studies were screened, and we included two published studies with 527 hospitalised 
patients. 523 patients had valid FebriDx results for Myxovirus resistance protein A (MxA), an antiviral 
host response protein.  The FebriDx test produced a pooled sensitivity of 0.920 (95% CI: 0.875-0.950) 
and specificity of 0.862 (0.819-0.896) compared with RT-PCR, where there was an estimated true 
COVID-19 prevalence of 0.405 (0.364-0.448) and overall FebriDx test yield was 99.2%. Patients were 
tested at a median of 4 days [interquartile range: 2:9] after symptom onset. No differences were 
found in a sub-group analysis of time tested since the onset of symptoms.  
 
Conclusions: Based on a large sample of patients from two studies during the first wave of the SARS-
CoV-2 pandemic, the FebriDx POC test had reasonable diagnostic accuracy in a hospital setting with 
high COVID-19 prevalence, out of influenza season. More research is required to determine how 
FebriDx would perform in other healthcare settings with higher or lower COVID-19 prevalence, 
different patient populations, or when other respiratory infections are in circulation. 
 
Trial registration: This work was based on a pooled analysis of anonymised data from two previous 
studies; the CoV-19POC study, described by Clark et al. (9), the “Southampton study” 
[ISRCTN:14966673, date registered: 18/03/2020]; and a study described by Karim et al. (13) the 
“Kettering study”. 
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Tests to diagnose COVID-19 are crucial to help control the spread of the disease and to guide 
treatment. Over the last few months, tests have been developed that can detect the SARS-CoV-2 
virus which causes COVID-19. These tests use complex machines in pathology laboratories accepting 
samples from large geographical areas. Sometimes it takes days for test results to come back. So, to 
reduce the wait for results, new portable tests are being developed. These point-of-care (POC) tests 
are designed to work close to where patients require assessment and care such as hospital 
emergency departments, GP surgeries or care homes. For these new POC tests to be useful, they 
should ideally be as good as standard laboratory tests so patients get their result quickly and can 
benefit from the best, safest care. 
 
In this study we looked at published research into a new test, FebriDx, which can detect the 
presence of any viral infection, including infections due to the SARS-CoV-2 virus, as well as bacterial 
infections which can have similar symptoms. The FebriDx result was compared with that obtained on 
the same patient’s throat and nose swab and using the standard COVID-19 viral laboratory test. 
We were able to analyse data from two studies with a total of 523 adult patients who were receiving 
emergency hospital care with symptoms of COVID-19 during the early stage of the UK pandemic. 
Almost half of the patients were diagnosed as positive for SARS-CoV-2 virus using standard 
laboratory COVID-19 viral tests. 
 
Our analysis demonstrated that the FebriDx POC test agreed 94 out of 100 times with the standard 
laboratory test results when FebriDx diagnosed the patient as free from COVID-19. However, FebriDx 
agreed only 82 out of 100 times with the standard laboratory test when FebriDx indicated that the 
patient had a COVID-19 infection. These differences have important implications for how these tests 
could be used. As there were far fewer FebriDx false results when the results of the FebriDx test 
were negative (6 out of 100) than when the results of the FebriDx test were positive (18 out of 100), 
we can have more confidence in a negative test result using FebriDx at the POC than a positive 
FebriDx result. 
 
Overall, we have shown that the FebriDx POC test performed quite well during the first wave of the 
COVID-19 pandemic when compared with laboratory tests, especially when the POC test returned a 
negative test. For the future, this means that the FebriDx POC test might be helpful in making a rapid 
clinical decision whether to isolate a patient with COVID-19-like symptoms arriving in a busy 
emergency department. However, our results indicate it would not completely replace the need to 
conduct a confirmatory laboratory test in certain cases. 
 
There are limitations to our findings. For example, we do not know if FebriDx will work in a similar 
way with patients in different settings such as in the community or care homes. Similarly, we do not 
know whether other viral and bacterial infections which cause similar COVID-19 symptoms, and are 
more common in the autumn and winter months, could influence the FebriDx test accuracy. 
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The global SARS-CoV-2 pandemic (1) has put considerable pressure on healthcare services 
worldwide. Health and care providers require diagnostic strategies to rapidly identify patients 
infected with SARS-CoV-2 to implement the accurate segregation of positive and negative patients in 
health and care facilities, and to ensure early administration of evidence-based therapies to patients 
with coronavirus disease 2019 (COVID-19) (2). The risks of nosocomial infection are high (3) and 
mechanisms to ensure that SARS-CoV-2 has limited transmission within hospitals, care facilities, and 
the community are an urgent priority as many countries begin to face a second wave of infection. 
 
There has been rapid development of novel clinical tests to support screening and diagnosis in both 
symptomatic and asymptomatic patients. In particular, there have been a number of molecular and 
antibody tests which manufacturers have developed for use at the point-of-care (POC) (4). POC tests 
for influenza have been adopted in many hospitals and other health and care facilities (5), where the 
rapid availability of results inform patient management, selection of the appropriate location for 
ongoing healthcare provision, and infection prevention and control (6, 7). In the emergency 
department setting for example, a rapid COVID-19 test result to aid triage of the patient into the 
appropriate COVID-19/non-COVID-19 sections of the hospital may contribute to a reduction in 
nosocomial infection, providing significant benefits to patient pathways, workflows, and outcomes 
(8).  
 
There is limited published evidence on the accuracy, reliability, and usability of many of the available 
POC tests for COVID-19, in particular, when used in-context within clinical settings with varying 
disease prevalence. Some pre-existing POC tests may have a role in the management of patients 
with suspected COVID-19. The FebriDx lateral flow device (LFD) (Lumos Diagnostics, Sarasota, 
Florida, USA) is a CE marked POC test that detects two host response proteins, myxovirus resistance 
protein A (MxA) and C reactive protein (CRP), in finger prick blood samples. This combination of MxA 
and CRP is designed to distinguish between viral and bacterial respiratory infection (9-11). MxA is an 
intracellular protein that is exclusively induced by type I interferon (IFN) and not by other cytokines 
expressed during bacterial infection (12, 13). Type I IFNs are produced in response to a wide range of 
viral infections and are found to be elevated in the presence of most acute viral infections (10), 
therefore providing strong theoretical grounds to expect MxA to rise in response to SARS-Cov-2 
infection.  The manufacturer’s intended use includes recommendations to use in patients older than 
2 years presenting within 3 days of an acute onset fever (exhibited or reported) and within 7 days of 
new onset respiratory symptoms consistent with a community-acquired upper respiratory infection 
(14). 
 
We undertook a systematic review and pooled diagnostic test accuracy study of available individual 
patient data (IPD) to evaluate the diagnostic accuracy of the FebriDx LFD compared to 
contemporaneous reverse transcriptase polymerase chain reaction (RT-PCR) testing to understand 
the performance of FebriDx in the identification of patients with COVID-19.  We did not limit this 
analysis to patients presenting within a certain number of days since the onset of symptoms in order 
to inform and identify all potential use cases within the pandemic.  
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We performed a systematic review with a pooled diagnostic test accuracy study of available IPD, and 
followed the STAndards for Reporting Diagnostic accuracy studies (STARD) checklist (15) 
(supplementary material 1). Although not formally a systematic review and meta-analysis of 
individual patient data (IPD) (16), we also followed the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA)-IPD checklist (PRISMA-IPD) (17) (supplementary material 2), 
where applicable. This study was conducted at pace as part of the CONDOR national test evaluation 




The inclusion criteria for studies were: published or un-published (preprint) diagnostic test accuracy 
studies; FebriDx used as the index test; RT-PCR used as a comparator test; and an adult population 
suspected of COVID-19 regardless of the time since symptom onset. The exclusion criteria were 
studies that were not a diagnostic test accuracy study. 
 
OVID Medline, LOVE Platform (Epistemonikos, Santiago, Chile), and the references from the Living 
Systematic Review on SARS-CoV-2 (19) were electronically searched on the 30th of July 2020, and 
again on the 1st of October 2020, by one author (JS) to identify diagnostic test accuracy studies 
reporting diagnostic accuracy statistics of FebriDx versus RT-PCR for SARS-CoV-2. The following 
keywords: “COVID-19”, “2019-nCOV”, “SARS-COV-2”, “novel coronavirus disease” AND “FebriDx” 
were used. No date, location or language restrictions were applied to the search results, and all of 
the databases included pre-prints. 
 
The abstracts of the search results were accessed and screened against the inclusion and exclusion 
criteria by two authors independently (SGU and KG). The two authors discussed, compared, and 
combined their findings, and if there was disagreement, adjudication was provided by a third author 
(AJA). If there was insufficient information in the abstract to exclude the study based on the 
inclusion and exclusion criteria, then a conservative approach of accessing the full text to perform 
the screening was taken to mitigate the risk of erroneously excluding relevant studies.   
 
Risk of bias (RoB) assessments were performed on the manuscripts of the identified studies that 
passed eligibility screening against the inclusion and exclusion criteria using the QUADAS-2 tool (20) 
for the quality assessment of diagnostic accuracy studies by two authors independently (SGU and 
KG). The QUADAS-2 binary prompts were deemed insufficient to fully capture the potential bias of 
the studies. The descriptive sections of the tool were therefore used to capture any other potential 
sources of bias not considered by the binary prompts. These additional aspects contributed to the 
final assessment for RoB. The two authors held a discussion to compare and combine their findings, 
and if there was disagreement, this was adjudicated by a third author (BCL).  
 
The Chief Investigators (CIs) of the identified studies that passed eligibility screening against the 
inclusion and exclusion criteria were approached via email to provide anonymised IPD. If IPD were 
not available, or not provided, then the study was excluded from further analysis. The minimum data 
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set that was requested from the CIs is outlined in supplementary material 3. Any queries relating to 
the study or provided data were communicated and resolved via email. The RoB assessments were 
performed prior to making contact with the CIs, and any additional information provided by the CIs 




Following receipt of the IPD, the FebriDx and RT-PCR results were summarised in 2x2 contingency 
tables for each study independently and also pooled across all studies. The following assumptions 
were applied. For FebriDx: a viral result (i.e. MxA positive [≥40 ng/ml], regardless of CRP positivity) 
was considered positive; a non-viral result (i.e. MxA negative [<40 ng/ml], CRP positive [≥20mg/L]) 
was considered negative; and a negative result (i.e. MxA negative [<40 ng/ml], CRP negative 
[<20mg/L]) was considered negative. For RT-PCR: if COVID-19 was detected the result was 
considered positive (COVID-19 + 'other' were also considered positive if studies used a respiratory 
panel that also tested for other viruses); and if COVID-19 was not detected the result was considered 




A complete case analysis approach was taken whereby cases with a completed and valid FebriDx and 
RT-PCR result pair were included, regardless of missing data within other fields. This was undertaken 
to maximise the available sample size for the pooled analysis. Cases that had missing FebriDx or RT-
PCR results were therefore excluded, in addition to cases that had a final indeterminate FebriDx or 
RT-PCR result for the pooled analysis.  However, to estimate overall test yield to allow interpretation 
of diagnostic accuracy estimates in spite of this, we included all cases with missing or invalid FebriDx 
test results.  
 
To determine if the study populations were similar, and to quantify any baseline and outcome 
imbalance, the distributions of variables were compared statistically between the included studies. 
Non-parametric two-sample Wilcoxon rank sum tests (two-sided) were used to compare numerical 
data, whilst two-sample tests for equality of proportions with continuity corrections were used to 
compare categorical data. Statistical significance was set at an alpha level of <0.05. Numerical data 
were summarised using the median and interquartile range, whilst categorical data were 
summarised using counts and proportions. 
 
To formally determine whether it was appropriate to pool the diagnostic accuracy results from the 
included studies, logistic regression was undertaken to investigate the study effect on the outcome 
of the RT-PCR test result, whilst controlling for the FebriDx test result. Thus a main effect for study, 
and an interaction effect between the FebriDx test result and study were included in the model. The 
following logistic regression model was constructed using a binomial error distribution and logit link 
function: 
 
𝑃𝐶𝑅 𝑡𝑒𝑠𝑡 𝑟𝑒𝑠𝑢𝑙𝑡 = 𝐹𝑒𝑏𝑟𝑖𝐷𝑥 𝑡𝑒𝑠𝑡 𝑟𝑒𝑠𝑢𝑙𝑡 + 𝑆𝑡𝑢𝑑𝑦 + (𝐹𝑒𝑏𝑟𝑖𝐷𝑥 𝑡𝑒𝑠𝑡 𝑟𝑒𝑠𝑢𝑙𝑡 ∗ 𝑆𝑡𝑢𝑑𝑦) 
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Diagnostic accuracy measures with 95% confidence intervals (CIs) were calculated from the 2x2 
contingency tables for each study independently and also pooled across studies (supplementary 
material 4). A sub-group analysis was also performed, with the pooled data stratified by the time 
tested since the onset of symptoms into two groups: 0 to 7 days, and >7 days. This was undertaken 
to determine whether the time tested since the onset of symptoms had an impact on the diagnostic 
accuracy of FebriDx. The following diagnostic accuracy measures were calculated across all study 
groups: 
 Test yield (the proportion of all patients tested with FebriDx that had a valid test result from 
FebriDx) 
 Apparent prevalence (the proportion of all patients with COVID-19 according to FebriDx) 
 Estimated true prevalence (proportion of all patients with COVID-19 according to RT-PCR) 
 Test sensitivity (proportion of patients with COVID-19, according to RT-PCR, that test 
positive by FebriDx) 
 Test specificity (proportion of patients without COVID-19, according to RT-PCR, that test 
negative by FebriDx) 
 Diagnostic accuracy (proportion of all FebriDx tests that give a correct result according to RT-
PCR) 
 Positive predictive value (PPV) (probability that patients with a positive FebriDx test have 
COVID-19 according to RT-PCR) 
 Negative predictive value (NPV) (probability that patients with a negative FebriDx test do not 
have the disease according to RT-PCR)    
 Positive likelihood ratio (probability of a patient who has COVID-19 according to PCR testing 
positive by FebriDx, divided by the probability of a patient who does not have the disease 
according to RT-PCR testing positive by FebriDx) 
 Negative likelihood ratio (probability of a patient who has COVID-19 according to RT-PCR 
testing negative by FebriDx, divided by the probability of a patient who does not have the 
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Fifteen studies were identified from the literature search, with seven studies excluded following 
deduplication. Six studies were excluded following screening against the inclusion and exclusion 
criteria, leaving two studies for potential inclusion (supplementary material 5). The CIs of the two 
studies were able to provide IPD which were included in analysis. The two studies were from the UK: 
a study from Southampton (CI = TWC) (9) and a study from Kettering (CI = RVR) (13). In addition to 
receiving the requested data underpinning the publications, an additional, unpublished dataset was 
made available to us from the Southampton study using the same methods as their initial 
publication (9).  
 
Risk of bias 
 
The results of the RoB assessment are provided in supplementary material 6. In the ‘Patient 
selection’ domain, the Southampton study was assessed to have an unclear RoB due to uncertainty 
around which patients were re-tested and which patients were excluded, and whether those with no 
CRP line [<20mg/L] on the FebriDx LFD but with concurrent laboratory CRP results of ≥20mg/L were 
excluded. In the ‘Index test’ domain, the Kettering study was assessed to have an unclear RoB due to 
patients with FebriDx positive and RT-PCR negative tests considered to be positive for COVID-19 if 
clinical suspicion was high. Due to this, there was concern regarding the applicability of the index 
test to the focus of this study. In the ‘Flow and timing domain’, the Kettering study was assessed to 
have a high risk of RoB due to the exclusion of one third of the patients for having symptoms longer 
than 7 days, however this did follow FebriDx’s instructions for use (14). 
 
Eligibility criteria, index test, and reference standard in the included studies 
 
Table 1 presents a summary of the eligibility criteria, index test, and reference standard used within 
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Table 1 - The eligibility criteria, index test, and reference standard of the included studies 
 Southampton (9) Kettering (13) 
Inclusion   Age ≥18 years old 
 Patient in ED, AMU, HDU, GICU, medical 
wards, or another location within 
Southampton General Hospital, University 
Hospital Southampton NHS Foundation Trust 
(UHS)  
 Can be recruited to the study within 24 hours 
of presentation to hospital  
AND 
 Has acute respiratory illness (ARI)† 
OR  
 Does not have ARI but is a suspected case of 
COVID-19 according to the current PHE case 
definition  
OR  
 Does not have ARI or fulfil the PHE case 
definition of a suspected case but testing for 
SARS-CoV-2 is considered necessary by the 
responsible clinical team  
 
 
 Age >16 years old 
 Require admission for at least one night with 
suspected COVID-19 infection 
 Meet the PHE criteria for swab testing for 
COVID-19 which includes the requirement of 
hospital admission and having:  
- Clinical or Radiological evidence of 
pneumonia or; 
- Acute respiratory distress syndrome or; 
- Influenza like illness (fever ≥37.8°C and 
at least one of the following respiratory 
symptoms, which must be of acute 
onset (within 7 days of enrolment): 
persistent cough (with or without 
sputum), hoarseness, nasal discharge or 
congestion, shortness of breath, sore 
throat, wheezing, sneezing)), or; 
 Inpatients with new respiratory symptoms 
or fever without another cause or worsening 
of a pre-existing respiratory condition 
Exclusion   Not fulfilling all the inclusion criteria  
 Declines nasal / pharyngeal swabbing 
 Consent declined or consultee consent 
declined  
 Already recruited to the study in the last 14 
days 
 Unable/unwilling to consent to the study 
 Does not meet PHE criteria for swab testing  
 Taking antibiotics or antivirals in the last 14 
days 
 Received Live vaccine in the last 14 days 
Index test  FebriDx  FebriDx 
Reference   QIAstat-Dx polymerase chain reaction (PCR) 
system for SARS-CoV-2 testing 
 PHE laboratory RdRp and envelope protein (E) 
gene PCR assays 
 PHE laboratory RdRp and envelope protein (E) 
PCR assays‡ 
‘ARI’ = ‘Acute respiratory illness’; ‘ED’ = ‘Emergency Department’; ‘AMU’ = ‘Acute Medical Unit’; ‘HDU’ = ‘High Dependency 
Unit’; ‘GICU’ = ‘General Intensive Care Unit’; ‘PHE’ = ‘Public Health England’; ‘RdRp’ = ‘RNA-dependent RNA polymerase’ 
†An episode of acute respiratory illness is defined as an acute upper or lower respiratory illness (including rhinitis, rhino-
sinusitis, pharyngitis, pneumonia, bronchitis and influenza-like illness) or an acute exacerbation of a chronic respiratory 
illness (including exacerbation of chronic obstructive pulmonary disease, asthma or bronchiectasis). For the study, acute 
respiratory illness as a provisional, working, differential or confirmed diagnosis must be made by a treating clinician;  
‡The European Centre for Disease Prevention and Control COVID-19 Case Definition was also used as a reference standard, 





In the Southampton study, consecutive patients were approached for participation at Southampton 
General Hospital, University Hospital Southampton NHS Foundation Trust, between the 20th March 
2020 and 29th April 2020. In the Kettering study, consecutive patients were approached for 
participation at Kettering General Hospital, Kettering General Hospital NHS Foundation Trust, 
between 16th of March and 7th of April 2020.  
 
When combined, both studies recruited hospitalised patients over 16 years of age with suspected 
COVID-19 between the 16th of March and 29th April 2020, however the Southampton study also 
allowed patients to be recruited who did not have an acute respiratory illness (ARI) or did not meet 
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In both studies, the results of the FebriDx test were not shared with the clinical teams and the 
readers of the FebriDx test lines were blinded to the RT-PCR results, and vice versa (9). In both 
studies, the finger prick blood samples for FebriDx were taken at the same time as the nose and 
throat swabs for RT-PCR (9, 13). In the Southampton study, the FebriDx result was read 
independently by two investigators and disagreements were further adjudicated by a third 
investigator. In the Kettering study, the FebriDx result was read by one investigator, however if the 




The Southampton study used the QIAstat-Dx RT-PCR system (Qiagen, Hilden, Germany) for analysing 
combined nose and throat swabs, which gave a binary readout of positive or negative for the 
detection of targets including SARS-CoV-2 (9), in addition to Public Health England (PHE) laboratory 
RNA-dependent RNA polymerase (RdRp) and envelope protein (E) RT-PCR testing for SARS-CoV-2. 
However, only results from the QIAstat-Dx RT-PCR system were available for the additional 
unpublished data from the Southampton study following their initial publication (9), so the results 
from the QIAstat-Dx RT-PCR system were used for all patients from the Southampton study to 
maintain within-study consistency for the purposes of this analysis. The Kettering study used Public 
Health England laboratory RdRp and envelope protein (E) RT-PCR testing for SARS-CoV-2 to analyse 




The flow of patients in the Southampton and Kettering studies are presented in supplementary 
material 7 and 8, respectively, and pooled data from both studies is presented in Figure 1.  
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Figure 1 - Flow diagram of the pooled data from the Southampton (Clark et al. (9) + additional 
unpublished data) and Kettering studies (Karim et al. (13))  
 
In the Southampton study, 500 patients were considered for testing with FebriDx, with 22 excluded 
(4.4%) as it was deemed inappropriate by the clinical team, or where the patient/carer declined 
participation in the study. Out of the 478 patients tested with FebriDx, 19 tests were initially invalid 
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(4%). FebriDx could not be repeated in 3 of the 19 initially invalid tested patients (15.8%). Out of the 
16 initially invalid tested patients that were retested, 1 was invalid (6.3%), and was subsequently 
retested again where the patient then received a valid test result upon a second retest. Considering 
all 20 invalid tests, 16 were due to blood clotting in the collection tube (80%), whilst 4 were due to 
there being no CRP line [<20mg/L] on the FebriDx device but with concurrent laboratory CRP results 
of ≥20mg/L (20%). 475 patients remained for analysis, resulting in a test yield of 99.4% 
(supplementary material 7). The Kettering study approached 75 patients for testing with FebriDx, 
where 26 were excluded (34.7%), with 25 due to symptoms being longer than 7 days, and 1 due to 
being immunosuppressed.  Out of the 49 patients tested with FebriDx, 1 test was initially invalid (2%) 
due to the inability to obtain enough blood. FebriDx could not be repeated in this patient as they 
were elderly, frail, and clinically unstable at the time of testing, and 48 patients remained for 
analysis, resulting in a test yield of 98% (supplementary material 8). 
 
This resulted in 575 patients being approached for testing with FebriDx when pooled, with 48 
excluded due to the aforementioned reasons (8.4%). Out of the 527 patients tested with FebriDx, 20 
tests were initially invalid (3.8%). FebriDx could not be repeated in 4 of the 20 initially invalid tested 
patients (20%). Out of the 16 initially invalid tested patients that were retested, 1 was invalid (6.3%), 
and was subsequently retested again where the patient then received a valid test result upon a 
second retest. 523 patients remained for the pooled analysis, resulting in an overall test yield of 
99.2%. 
 
Patient population and outcome 
 
The patient population and outcome in the Southampton study, Kettering study, and pooled data 
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Table 2 - Patient population and outcome in the included studies and pooled data from both studies 
 Southampton (9) Kettering (13) Pooled Comp 
 n/med %/IQR n/med %/IQR n/med %/IQR p value 
Population        
Valid tests (n) 475 --- 48 --- 523 --- --- 
Age (median, IQR) 69 52-81 67 54.3-78 69 52-81 0.59 
Male (n, %) 244 51.4 32 66.7 276 52.8 0.06 
Symptom duration (med, IQR)† 5 1-10 3 2:5 4 2:9 0.15 
Symptoms‡:        
     Sore throat (n %)   92   24.7   0   0.0 --- --- --- 
     Rhinorrhoea (n, %)   91   24.4   0   0.0 --- --- --- 
     Wheeze (n, %)   135   35.5   0   0.0 --- --- --- 
     SOB (n, %)   297   71.9   38   79.2 --- --- --- 
     Pleuritic pain (n, %)   96   25.3   2   4.2 --- --- --- 
     Cough (n, %)   240   59.0   40   83.3 --- --- --- 
     Sputum (n, %)   105   27.8   0   0.0 --- --- --- 
     Fever (n, %)   192   48.2   41   85.4 --- --- --- 
     Chills (n, %)   165   43.4   0   0.0 --- --- --- 
     Fatigue (n, %)   255   68.0   6   12.5 --- --- --- 
     Reduced appetite (n, %)   224   60.2   2   4.2 --- --- --- 
     Headache (n, %)   148   39.8   0   0.0 --- --- --- 
     Myalgia (n, %)   115   31.1   3   6.2 --- --- --- 
     Diarrhoea (n, %)   97   25.5   3   6.2 --- --- --- 
     Abdominal pain (n, %)   60   16.0   3   6.2 --- --- --- 
     Anosmia (n, %)   66   18.8   0   0.0 --- --- --- 
Outcome        
Death‡ 74 17.8 12 25.0 --- --- --- 
‘Comp’ = ‘Comparison’; ‘n’ = ‘number’; ‘med’ = ‘median’; ‘IQR’ = ‘interquartile range’; ‘SOB’ = ‘shortness of breath’ 
†Symptom duration is the number of days from symptom onset until the samples were obtained for testing by FebriDx/RT-
PCR (samples were collected for FebriDx and RT-PCR at the same time) 




Symptom and outcome data were provided as requested for both studies, but due to 
methodological differences between the studies in how these data were defined and captured, they 
were excluded from statistical analyses. The Southampton study recorded symptoms in the 
prospectively stipulated categories presented in Table 2, whereas the Kettering study recorded free 
text symptoms. For presentational purposes only, two authors (SGU, AJA) reviewed each of the free 
text fields in the Kettering study independently and applied the same categories as the Southampton 
study, with no disagreements requiring adjudication by a third author. The Southampton study 
reported death at 30 days following admission, whereas the Kettering study reported death at the 
end of the index admission.  
 
No statistically significant differences were found between the populations of the Kettering and 
Southampton studies in terms of age (p = 0.59), sex (p = 0.06), and symptom duration (p = 0.15), 
although the sex distributions almost reached statistical significance, with the Kettering study having 
a slightly higher proportion of males (66.7% vs. 51.4%).  
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In the logistic regression analysis to investigate the study effect on the outcome of the RT-PCR test 
result, none of the included terms were statistically significant: FebriDx test result (b = 18.6; p = 
0.98); the study (b = 13.9; p = 0.98); and an interaction term between FebriDx test result and the 
study (b = -14.5; p = 0.98). The interaction term was therefore removed from the hierarchical model, 
and in the reduced model, as expected, the FebriDx test result was highly statistically significant (b = 
4.24; p<0.001), and the study effect was still not statistically significant (b = -0.32; p=0.49). This 
result suggests little study effect on the outcome of the PCR test result, whilst controlling for the 




The Southampton and Kettering studies had a test yield of 99.4% and 98%, respectively, and when 
combined, a test yield of 99.2% was found. These valid tests were presented in 2x2 contingency 
tables for the Southampton study, Kettering study, and pooled data (including sub-group analyses) 
from both studies in Figure 2, with the diagnostic accuracy results calculated for the Southampton 
study, Kettering study, and pooled data (including sub-group analyses) from both studies presented 
in Table 3.  
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Figure 2 - 2x2 contingency tables from the Southampton study (Clark et al. (9) + additional 
unpublished data), Kettering study (Karim et al. (13)), and pooled [all and sub-group] data from both 
studies. One patient was excluded from the ‘Pooled [sub-group]’ analysis due to missing symptom 
duration data. Please note that data from the ‘Pooled [sub-group]: symptoms >7 days’ were from the 
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Table 3 – Diagnostic accuracy results for the included studies and pooled data from both studies 
 Southampton (9) 
 
n = 475  
Kettering (13) 
 
n = 48 
Pooled [all] 
 
n = 523 
Pooled [sub-group]: 
symptoms 0-7 days‡ 
n = 372  
Pooled [sub-group]:  
symptoms >7 days‡¥ 
n = 150 
 Estimate 95% CI Estimate 95% CI Estimate 95% CI  Estimate 95% CI Estimate 95% CI 
Apparent prevalence 0.427 0.384-0.472 0.729 0.589-0.835 0.455 0.413-0.498 0.444 0.394-0.494 0.487 0.408-0.566 
True prevalence† 0.381 0.338-0.426 0.646 0.504-0.766 0.405 0.364-0.448 0.392 0.344-0.443 0.440 0.363-0.520 
Sensitivity 0.906 0.854-0.941 1.000 0.869-1.000 0.920 0.875-0.950 0.932 0.877-0.964 0.894 0.794-0.951 
Specificity 0.867 0.824-0.902 0.765 0.522-0.910 0.862 0.819-0.896 0.872 0.821-0.910 0.833 0.738-0.899 
Accuracy 0.882 0.85-0.908 0.917 0.799-0.972 0.885 0.855-0.910 0.895 0.860-0.923 0.860 0.795-0.907 
PPV 0.808 0.748-0.856 0.886 0.735-0.961 0.819 0.765-0.863 0.824 0.759-0.875 0.808 0.702-0.883 
NPV 0.938 0.902-0.961 1.000 0.734-1.000 0.940 0.906-0.963 0.952 0.912-0.975 0.909 0.821-0.958 
PLR 12.926 8.545-22.476 Inf 4.473-Inf 13.736 9.087-23.993 17.062 9.978-36.295 8.890 4.886-23.923 
NLR 0.205 0.149-0.266 0.114 0.028-0.255 0.192 0.142-0.247 0.185 0.126-0.249 0.211 0.117-0.319 
‘CI’ = ‘confidence interval’; ‘PPV’ = ‘positive predictive value’; ‘NPV’ = ‘negative predictive value’; ‘PLR’ = ‘positive likelihood ratio’; ‘NLR’ = ‘negative likelihood ratio’; ‘Inf’ = ‘infinity’; 
†Estimated true prevalence (i.e. proportion of all patients with COVID-19 according to RT-PCR) 
‡One patient was excluded from the ‘Pooled [sub-group]’ analysis due to missing symptom duration data 
¥These data were from the Southampton study only 
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The estimated true and apparent COVID-19 prevalence were the only statistically significant 
differences between the studies in the diagnostic accuracy measures (both p<0.001), with the 
Kettering study experiencing a higher COVID-19 prevalence (estimated true prevalence = 0.646 (95% 
CI: 0.504-0.766)) than the Southampton study (estimated true prevalence = 0.381 (0.338-0.426)).  
 
The pooled results from 523 patients gave an estimated sensitivity of 0.920 (0.875-0.950) and 
specificity of 0.862 (0.819-0.896) for the FebriDx test, with an overall diagnostic accuracy of 0.885 
(0.855-0.910) at an estimated true prevalence of 0.405 (0.364-0.448) (Table 3). The PPV was 0.819 
(0.765-0.863) and NPV was 0.940 (0.906-0.963).  
 
One patient was excluded from the sub-group analyses of the pooled results due to missing 
symptom duration data. In these analyses, no statistically significant differences were apparent 
between the 372 patients that were tested between 0 and 7 days after symptom onset and the 150 
patients that were tested more than 7 days after symptom onset in any of the diagnostic accuracy 
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In this systematic review and pooled analysis of IPD, we found that the FebriDx LFD had a pooled 
sensitivity of 0.920 (95% CI: 0.875-0.950) and specificity of 0.862 (0.819-0.896) for COVID-19 across 
two studies performed within acute hospitals in the UK when compared to RT-PCR on nose and 
throat swabs during the first wave of the SARS-CoV-2 pandemic. There were no other published data 
on the diagnostic accuracy of FebriDx, with the overall evidence base in terms of studies performed 
remaining small. The two studies did, however, include a total of 523 patients, achieving a large 
sample size for the pooled analysis. 
 
Testing with FebriDx produced an initial test failure rate of 3.8% (20 out of 527 patients tested). In 
those patients where re-testing was performed, most were valid upon the first re-test (15 out of 16 
patients), and only one patient required a second re-test to produce a valid result. Most test failures 
were described as being the result of blood clotting within the collection tube, and therefore not 
being released into the device for analysis. 
 
The duration between onset of symptoms and the patient being tested did not seem to have an 
impact on the diagnostic accuracy of FebriDx, with no statistically significant differences evident 
between the two sub-groups of 0 to 7 days and greater than 7 days after symptom onset. However, 
only one of the studies included patients with symptom onset after 7 days, so this finding is not from 
a pooled analysis. 
 
All patients included in the pooled analysis were from the acute hospital setting, and such findings 
must be extrapolated with caution to other patient groups and settings. Further context-specific 
evaluation would be required in order for FebriDx to be used in other patient groups where 
performance has not yet been demonstrated; such as children, immunocompromised and cancer 
patients, and those who are asymptomatic or pauci-symptomatic. Further, taking care homes as an 
example setting, the mean age of residents is 85 years (21), and all care home residents are 
significantly affected by frailty. The high prevalence of immunosenescence in this group is such that 
CRP and MxA results might be significantly attenuated (22). It is clear that hospital data cannot be 
extrapolated to such a group and further context-specific evaluation would be required in other 
settings.  
 
In the context of older, more frail, community dwelling populations where delirium is a common, 
sensitive, but non-specific presentation of COVID-19 (23), the ability to rule out viral and bacterial 
infections as the cause of delirium during an outbreak may be even more important than the ability 
to detect them.  Further work is therefore required to look at the NPV of FebriDx in populations 
where such information may be of use. 
 
It should also be noted that specific treatments (neuraminidase inhibitors) are available and 
recommended for use during influenza outbreaks, and an increasing body of evidence supports 
different interventions (remdesivir and dexamethasone) for use in cases of COVID-19 (2, 24).  The 
ability to distinguish between different types of viral infection is important and the value added by 
FebriDx in the context of already wide availability of influenza POC testing is unclear. 
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Although not a direct test for the presence of SARS-CoV-2 infection, the performance measures 
reported in this analysis are comparable to results from other studies of FebriDx in detecting the 
presence of respiratory viral infections (10). As a raised MxA level is not diagnostic of SARS-CoV-2 
due to its non-specific response to a number of respiratory infections, the optimal use case of the 
FebriDx test is unlikely to be for ‘ruling in’ COVID-19.  In a hospital setting, if FebriDx was used to 
cohort patients to wards incorrectly, then the unspecific nature of the result may lead to the 
exposure of patients to potentially serious co-infection. Recent evidence has suggested that the risk 
of death from co-infection of SARS-CoV-2 and influenza was nearly double that of SARS-CoV-2 alone, 
43.1% vs 26.9% (25). However, the simplicity of a fingerprick blood test with a 10-minute turnaround 
time could enable rapid ‘rule out’ of COVID-19 in patients who have low concentrations of MxA. In a 
hospital setting, those patients could be potentially sent to non-COVID areas of a hospital.  
 
In the pooled analysis presented in this study, the NPV was 0.940 at a prevalence of 0.405. The 
performance of FebriDx as a rule out test at a lower prevalence is likely to be better. In the 
community, the test could potentially be used to allow relatives to visit care homes residents; to 
facilitate air travel; or to support schools or universities. However, it is imperative to evaluate this 
test within the appropriate patient populations in-context for each of these use cases before making 
recommendations. In this study, we have only identified evidence relating to use in symptomatic 
patients presenting to hospital with suspected COVID-19. 
 
Implications for practice 
 
Whilst diagnostic performance measures were reasonably high, our findings are limited by the 
uncertain generalisability to longer durations of symptoms (more than a week), to different 
healthcare settings, and to different phases of the pandemic as prevalence rates will vary.  
 
The utility of FebriDx may be limited to its ability to rule out acute COVID-19 infection because a 
positive result does not specify which respiratory viral pathogen is present. However, a sensitivity of 
0.920 will lead to a false negative result in almost one in ten positive patients. This is an important 
consideration for settings with a high prevalence of disease in tested patients. Testing protocols 
would need to be developed carefully to ensure the correct use of the test, likely as a triage test in 
conjunction with RT-PCR.  
 
If further evidence confirms the diagnostic characteristics of FebriDx in a hospital setting then it may 
be of greatest utility when deployed in a triaging capacity. For example, enabling the allocation of 
patients to wards based on the likely risk of SARS-CoV-2 whilst confirmatory RT-PCR testing is 
sought. This should, however, be used with caution due to the potential increased risk that co-
infection poses to patients with SARS-CoV-2. The use of the FebriDx LFD should be carefully 
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The reference standard of RT-PCR on nose and throat swab samples is imperfect, and while 
commonly used as a reference test, it is not a gold standard (26). RT-PCR has shown limited 
diagnostic performance characteristics, particularly with the production of false negative results in 
patients presenting in an emergency with suspected COVID-19 (27-29). An imperfect reference 
standard in this case, which most likely produced false negative results, would be likely to produce 
an underestimate of both sensitivity and specificity. If additional clinical and diagnostic data were 
available for both studies, this analysis would have benefitted from the use of a composite reference 
standard (30) or latent class analyses with instrumental variables to minimise the probability of such 
error or bias (31-33). Although both studies used RT-PCR as the reference standard, different RT-PCR 
tests were used across the studies. The accuracy of the different RT-PCR tests used will vary between 
methods, and as these methods were further developed during the pandemic, this leads to an 
inconsistent reference standard. This suggests that the pooled diagnostic accuracy estimates should 
be treated with caution. 
 
Both studies were conducted during the first peak of the SARS-CoV-2 pandemic in the UK 
(March/April 2020), where the prevalence of COVID-19 was high. The pooled diagnostic accuracy 
results (particularly PPV and NPV) should only be interpreted within this specific phase of the 
pandemic, and not extrapolated to other phases where a lower prevalence of COVID-19 was evident.  
A key additional issue will occur when there are increased rates of several other viruses and bacteria 
circulating, most notably during the winter season. The possibility of co-colonisation/infection at 
such times will be a challenge for diagnostic accuracy evaluations.  In particular, it is likely that the 
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Based on a large sample of patients from two studies during the first wave of the SARS-CoV-2 
pandemic, FebriDx had reasonable diagnostic accuracy in a hospital setting with high COVID-19 
prevalence, out of influenza season. We cannot be certain how FebriDx would perform in other 
healthcare settings with higher or lower COVID-19 prevalence or at times year when other 
respiratory infections may affect diagnostic performance.  Further evidence is needed on FebriDx’s 
diagnostic performance and utility in different populations, clinical and non-clinical settings.   
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This work was based on a pooled analysis of anonymised data from two previous studies; the CoV-
19POC study, described by Clark et al. (9), the “Southampton study” [ISRCTN:14966673, date 
registered: 18/03/2020]; and a study described by Karim et al. (13), the “Kettering study”. The 
Southampton study was approved by the South Central - Hampshire A Research Ethics Committee: 
REC reference 20/SC/0138, on the 16th March 2020. The protocol is available at: 
https://eprints.soton.ac.uk/439309/1/CoV _ 19POC _ Protocol _ v1.1 _eprints.pdf.  The Kettering 
study was approved by the Kettering General Hospital Ethics Committee. Informed consent was 
obtained from all participants and failure to consent was considered an exclusion criterion in both 
studies. 
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List of abbreviations 
 
AMU Acute Medical Unit 
ARI Acute respiratory illness 
b Regression coefficient (estimate) 
CI Chief Investigator 
CI Confidence intervals 
COVID-19 Coronavirus disease 2019 
CRP C-reactive protein 
ED Emergency Department 
GICU General Intensive Care Unit 
HDU High Dependency Unit 
IPD Individual patient data 
IQR Interquartile range 
LFD Lateral flow device 
MxA Myxovirus resistance protein A 
NLR Negative likelihood ratio 
NPV Negative predictive value 
p P value 
PHE Public Health England 
PLR Positive likelihood ration 
POC Point-of-care 
PPV Positive predictive value 
RT-PCR Reverse transcriptase polymerase chain reaction 
RdRp RNA-dependent RNA polymerase 
RoB Risk of bias 
SOB Shortness of breath 
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Supplementary material  
 
Supplementary material 1: ‘Supplementary material 1.pdf’ presents the STARD checklist. 
 
Supplementary material 2: ‘Supplementary material 2.pdf’ presents the PRISMA-IPD checklist. 
 
Supplementary material 3: ‘Supplementary material 3.pdf’ presents the minimum data set that was 
requested from the Chief investigators (CIs) of the included studies. 
 
Supplementary material 4: ‘Supplementary material 4.pdf’ presents the methods for calculating the 
diagnostic accuracy measures. 
 
Supplementary material 5: ‘Supplementary material 5.pdf’ presents the PRISMA-IPD flow diagram. 
 
Supplementary material 6: ‘Supplementary material 6.pdf’ presents risk of bias (RoB) assessments 
for the included studies. 
 
Supplementary material 7: ‘Supplementary material 7.pdf’ presents the flow of patients in the 
Southampton study. 
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